Every material Form 8-K HeartCore Enterprises, Inc. has filed with the SEC since June 25, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
HeartCore Enterprises reported second-quarter 2026 results with revenue up 71.6% to $321,000, while the company posted a net loss of $2.0 million, compared with net income of $1.1 million a year earlier. The company also said it completed the divestiture of Sigmaways and agreed to sell its 51% stake in HeartCore Luvina, and that it regained Nasdaq minimum bid price compliance.
Q2 2026 revenue rose to $321,000 from $187,000, driven by software development services, partly offset by lower Go IPO consulting revenue.
Q2 2026 net loss was $2.0 million versus net income of $1.1 million, with gross loss of $70,000 and a shift from other income to other expenses.
Six-month net loss widened to $4.0 million from $2.1 million; cash and cash equivalents were $587,000 as of June 30, 2026.
The company has agreed to divest its 51% equity interest in HeartCore Luvina to Luvina Software Joint Stock Company and completed the Sigmaways divestiture.
HeartCore Enterprises agreed on August 3, 2026, to sell its entire 51% interest in HeartCore Luvina Vietnam Company Limited to Luvina Software Joint Stock Company, which already holds the remaining 49%. The price is JPY 29,000,000 (approximately $184,093), and closing is expected on or before August 14, 2026. The filing does not disclose the venture's revenue, profit, or the gain or loss on the sale, so its effect on shareholders' results cannot be measured from this document.
Company sells its entire 51% stake in HeartCore Luvina Vietnam Company Limited to Luvina Software Joint Stock Company
Price is JPY 29,000,000 (approximately $184,093), per the Transfer Agreement dated August 3, 2026
Closing is expected on or before August 14, 2026
CEO Sumitaka Kanno says the sale lets management focus resources on the Go IPO consulting and financial services business
HeartCore Enterprises agreed on June 22, 2026 to sell its entire 51% stake in Sigmaways, Inc. and $2.19 million in Sigmaways promissory notes to Semaphore Technologies, with the closing on the same day. The up-to-$650,000 price consists of a $1,000 cash payment at closing and an earn-out of up to $649,000 tied to Sigmaways' future gross revenue, and HeartCore also gave up a $350,000 SAFE note as part of a mutual release. The company says the sale removes a loss-making subsidiary with a shareholders' deficit of about $3.6 million (unaudited) as of March 31, 2026 from its consolidated results.
Sold 229,500 shares (51% ownership) of Sigmaways and $2.19 million in promissory notes to Semaphore Technologies; closed June 22, 2026.
Purchase price up to $650,000: $1,000 cash at closing plus an earn-out of up to $649,000.
Earn-out equals 10% of Sigmaways gross revenue above $5,500,000 over the 12 months after closing, payable within 10 days after that period.
Sigmaways had a shareholders' deficit of about $3.6 million (unaudited) as of March 31, 2026; HeartCore contributed a $350,000 SAFE note from Heart-Tech Health, Inc. in a mutual release.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HeartCore Enterprises, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →